Exosome Skin Treatments in the UK: Evidence, Routes and Safety

Exosome Skin Treatments in the UK: Evidence, Routes and Safety

Exosomes are one type of extracellular vesicle released by cells. They can carry proteins, lipids and genetic material between cells, which makes them an active area of laboratory and clinical research. That biological interest does not prove that every product marketed with the word ‘exosome’ is effective, equivalent or suitable for use in a cosmetic procedure.

Exosomes are not stem cells

Exosomes are vesicles rather than living cells. A phrase such as ‘stem-cell-derived exosomes’ describes a proposed source; it does not mean that a finished product contains viable stem cells or that a cosmetic procedure is stem-cell therapy. Products can differ in source, manufacturing, purification, contents, concentration, storage and intended use. Evidence for one preparation cannot be transferred automatically to another.

What the human skin evidence currently shows

Recent systematic reviews report preliminary signals for short-term changes in measures such as hydration, elasticity, wrinkles or pigmentation after selected extracellular-vesicle preparations. The certainty remains limited. Most studies were not randomised, methods and products differed, risk of bias was often substantial and follow-up was short. The evidence does not establish guaranteed rejuvenation, healing, collagen production, a set percentage improvement or a durable result for every product or patient.

Topical use, microneedling, mesotherapy and injection are different

A cosmetic applied to intact skin, a preparation placed on punctured skin after microneedling, and an injected product are different interventions with different evidence and risks. Do not inject a topical product or use it against its instructions. Microneedling itself can cause redness, discomfort, dryness, bleeding, bruising and peeling; pigment change, cold-sore reactivation, infection and scarring are less common possibilities. Evidence for a combined procedure must address the exact product, device, depth and route.

UK product and claim checks

In Great Britain, a cosmetic product must have a Responsible Person, a safety report within its Product Information File, appropriate notification and evidence for its marketing claims. The MHRA considers claims, composition, intended purpose and mode of action when deciding whether a product is a medicine or medical device. Availability for purchase, professional-only wording or use in another country does not by itself prove UK approval for a specific medical or cosmetic claim.

Claims require finished-product evidence

Ingredient descriptions, laboratory mechanisms, testimonials and uncontrolled before-and-after photographs do not establish what a finished product will do. In a 2026 ruling, the ASA found that small uncontrolled studies and ingredient or delivery-system explanations did not substantiate prominent lifting and rejuvenation claims for a commercial exosome-labelled cosmetic. Evidence must match the finished product, route, outcome and population.

Dr Sknn clinic, availability and price facts

Wilmslow is Dr Sknn's primary clinic, Didsbury is active and Leigh is closed. The exact exosome-labelled product, source, intended route, UK status and eligible practitioner for a particular appointment have not been established in this evidence file, so this guide does not assert that every listed procedure is currently available at either active clinic. Check the exact live booking entry before travelling. Doctor consultations are free; a £50 reservation fee may secure an appointment and is not a consultation charge. Current treatment prices are listed on the official Dr Sknn pricing board.

What to verify before a procedure

Ask for the exact product name, manufacturer, biological source, full ingredient and allergen information, batch traceability, sterility evidence where relevant, storage instructions, UK Responsible Person or other applicable regulatory status, intended route and evidence for the exact product-procedure combination. Also ask who will perform it, the realistic degree and duration of change, the full course and cost, material risks, alternatives, aftercare and the plan for infection, allergy, pigment change or another unexpected reaction.

Hair-loss evidence is a separate question

Hair loss has several causes and requires a diagnosis before treatment choices are made. Skin-rejuvenation research cannot be used as proof of hair regrowth. See the separate exosomes and hair-loss evidence guide for the limited human evidence and the questions to ask.

Sources

MHRA: how claims, composition and function affect medicine status; OPSS: cosmetic-product safety, notification and claim requirements in Great Britain; Systematic review of human exosome-based skin-rejuvenation studies; Systematic review and GRADE assessment of extracellular-vesicle facial-rejuvenation evidence; FDA: microneedling-device uses, combination limits and risks; ASA ruling: evidence required for exosome-labelled cosmetic claims.